title: Adverse Reactions to Biologic Therapy.
abstract: Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed. Desensitization can be considered for reactions suggestive of IgE-mediated mechanisms, but allergists/immunologists should be involved in managing these patients.
authors.affiliation: Division of Allergy and Immunology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, F4.206, Dallas, TX 75390-8859, USA. Electronic address: sheenal.patel@outlook.com.
authors.forename: Sheenal V
authors.initials: SV
authors.lastname: Patel
authors.affiliation: Division of Allergy and Immunology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, F4.206, Dallas, TX 75390-8859, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Khan
mesh_terms: D001688:Biological Products / Q000009:adverse effects* / Q000627:therapeutic use; D001691:Biological Therapy / Q000009:adverse effects* / Q000379:methods; D003888:Desensitization, Immunologic / Q000379:methods; D019468:Disease Management; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans
chemical_list: D001688:Biological Products
keywords: Biologic agents; Delayed reaction; Drug desensitization; Infusion reaction; Monoclonal antibodies; Omalizumab; Rituximab